The world’s first global systematic review suggests the shingles vaccine could lower the risk of heart attack and stroke in adults. Analyzing 19 studies, researchers found that vaccination was associated with an 18% reduced risk of cardiovascular events in adults aged 18 and older, with a 16% reduction for those over 50.
Shingles, caused by the reactivation of the herpes zoster virus, can lead to painful rashes and severe complications such as long-term nerve pain, deafness, and in rare cases, blindness. The vaccine is typically recommended for older adults or those with weakened immune systems, but the study indicates potential cardiovascular benefits for younger adults as well.
Experts note that shingles triggers inflammation in the body, which is a known contributor to heart disease and stroke. By preventing shingles, vaccination may help reduce this inflammation, potentially protecting the heart and circulatory system. While the findings are promising, further research is needed to confirm the causal link and explore the mechanisms involved.
The NHS has announced an expansion of eligibility for the shingles jab, starting September 1, covering adults aged 18–49 with severely weakened immune systems. Researchers hope continued study could broaden recommendations and highlight vaccines as a tool for cardiovascular health, beyond infection prevention.
